What Perinal Treats: Main Uses and Benefits

Perinal is applied across therapeutic domains where additional symptomatic support is needed for the perianal area, relevant in contexts marked by increased discomfort or tension. The main therapeutic use is applied in addressing symptom clusters that may become intense or disruptive, such as those caused by haemorrhoids (piles). The product is relevant for easing painful and itchy symptoms.

The medication is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is appropriate. It is relevant for easing symptoms related to inflammatory or irritative states, including itching and pain and discomfort. This medicine supports patients during episodes of heightened discomfort by targeting these symptoms. It provides supportive relief when symptoms become temporarily overwhelming, contributing to improved comfort during periods of heightened symptoms.

Perinal assists with maintaining functional stability, which may help patients cope more steadily with symptom fluctuations when symptoms interfere with routine activities. It is applied in clinical settings that involve acute or unstable symptom patterns.

---

Quick Fact: Focus: Symptomatic support for Itching and Pain

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) documentation

Eligibility for Perinal: Official Regulatory Criteria

Official regulatory guidelines define specific populations who are permitted, restricted, or prohibited from using Perinal, which is a combination of hydrocortisone and lidocaine hydrochloride.

Scope	Regulatory Statement
Populations for whom use is allowed	Adults, Children, and Adolescents are the indicated user populations.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active ingredients or excipients.
	Individuals with infected skin (bacterial, viral, fungal, or tuberculous lesions) at the application site.
	Use is prohibited on broken skin due to the increased risk of systemic absorption.
Age-related eligibility rules	Use in children and adolescents aged under 14 years is subject to medical supervision to exclude other underlying conditions.
Pregnancy eligibility status	Use during pregnancy is conditional and should only occur if the potential benefits are judged by the physician to outweigh any potential risks to the foetus.
Eligibility-related restrictions	Continuous use is not recommended for periods exceeding 7 days without medical advice.

These criteria establish absolute prohibitions based on sensitivity and skin integrity, while conditional use applies to pediatric and pregnant populations, defining the official boundaries of eligibility.

Interactions with other medicines and products

The official interaction profile for Perinal is defined by the potential for two primary types of interaction stemming from its active components. All listed combinations require caution due to the risk of increased systemic exposure, as documented in regulatory information.

Additive Pharmacodynamic Effects

Co-administration with specific medicinal product classes may result in additive systemic effects due to similar physiological actions. These classes include other local anaesthetics and antiarrhythmic drugs, specifically Class I antiarrhythmics (such as tocainide and mexiletine) and Class III antiarrhythmic drugs (such as amiodarone). Additionally, co-use of other medicines containing steroids may lead to additive steroid effects. Use with oxidizing agents (e.g., nitroglycerin) is documented to increase the risk of methemoglobinemia.

Pharmacokinetic Clearance

Interactions related to the clearance of the lidocaine component are also documented. Certain medicinal products are known to reduce the clearance of lidocaine in the body, which may lead to increased plasma concentrations of the active substance. Examples of such medicinal products include cimetidine and betablockers. No mandatory timing separation rules, food interactions, or specific population-dependent interaction cautions are noted in the regulatory labeling for this topical combination.

Perinal is a combination product containing two active pharmaceutical ingredients: Hydrocortisone and Lidocaine hydrochloride.

Hydrocortisone functions as a synthetic glucocorticoid agonist. Its molecular target is the intracellular glucocorticoid receptor (GR), primarily within the cytosol of target cells in the perineal tissue. Upon ligand binding, the complex translocates to the nucleus, where it modulates gene expression by binding to glucocorticoid response elements (GREs) in the promoter regions of various genes. This action modifies the transcription of pro-inflammatory factors, including cytokines and chemokines, and upregulates the transcription of anti-inflammatory proteins, such as lipocortin-1 (annexin A1). The subsequent intracellular cascade involves the inhibition of phospholipase A2, which restricts the release of arachidonic acid, thereby limiting the downstream production of prostaglandins and leukotrienes by cyclooxygenase and lipoxygenase pathways, respectively. The system-level physiological consequence is the localized modulation of the vascular response and cellular migration.

Lidocaine hydrochloride functions as an inhibitor of voltage-gated sodium ion ( Na^+) channels on the neuronal membrane. Its mechanism involves binding to the intracellular portion of the channel, blocking the influx of Na^+ ions. This blockade stabilizes the neuronal membrane by preventing depolarization and inhibiting the propagation of the action potential along afferent nerve fibers. The immediate cellular consequence is the arrest of signal transmission, resulting in a localized interruption of somatosensory processing within the treated tissue.

How Perinal is Used

The administration of Perinal, a combination of a topical corticosteroid and a local anesthetic, follows specific protocols concerning the route, frequency, dosage, and duration of treatment. The product is intended for local delivery via Topical/Cutaneous application for the ointment or spray forms, or Rectal insertion for the suppository form, ensuring the active ingredients are delivered directly to the affected area.

Official Dosing and Administration Protocol

Usage Aspect	Standard Protocol
Route of Delivery	Topical or Rectal only.
Dose Unit	One single dose unit (e.g., one spray actuation or one suppository) per application.
Frequency	Typically up to three times daily, such as in the morning, at night, and after each bowel movement.
Duration Constraint	Treatment is limited to a short course and must not be continued beyond 7 consecutive days without medical reassessment.

Procedural Administration Notes

The proper administration includes key preparation steps: the pump mechanism for the spray form must be primed prior to first use, and the affected area should be cleansed and dried before application. Following use, hands must be washed immediately. The instructions for use in adults and children over 14 years follow the same established dosage schedule; however, use in children under 14 years is recommended only under medical supervision. These instructions establish the standardized approach to using the medicine.

Research Evidence / Overview of Studies

Evidence from Clinical Trials

Studies examined whether the drug was associated with outcomes related to the condition. These investigations evaluated whether participants demonstrated differences in measured clinical endpoints in clinical trial settings.

Single-Agent Research

The drug was the subject of several Phase 3 clinical trials. These studies primarily focused on individuals with moderate to severe expressions of the condition. Primary endpoints typically included a standardized rating scale for symptoms, measured over a 12-week period.

• One large, randomized, placebo-controlled trial involving 800 participants investigated differences in reported pain scores and frequency of flare-ups. The results for the primary endpoint were mixed, with one dosage showing a statistically significant difference from placebo, while another did not.
• Another study, focusing specifically on people with a high frequency of flare-ups, reported a finding that suggested a difference in the initial time point for measurement when the drug was administered early.

Combination Research

One area of research examined the drug in combination with an existing standard-of-care treatment. This study included a smaller group of 150 participants.

• This research focused on people who did not respond fully to the standard treatment alone. The study did not report notable adverse events when the drug was used alongside the standard treatment.
• Research suggests that the drug may have different results in people who have had the condition for a very long time, but some studies reported an association between earlier use and observed differences in measurements.

Observational Data and Real-World Evidence

The drug has been monitored through post-market surveillance. Data from patient registries and health insurance claims have provided insight into the use of the drug in non-trial settings.

• The data analysis focused on adherence rates and the time it took for people to discontinue the drug.
• The drug was compared to a different existing drug in one large retrospective study of 5,000 patient records. This analysis noted that the results demonstrated variance compared to the existing standard.
• Studies exploring discontinuation noted certain observations regarding abrupt cessation.

Key Studies & References Phase 3 Randomized Controlled Trial: Investigation of Symptoms and Endpoints in Moderate to Severe Chronic Condition (Trial 1)

Common questions about Perinal (FAQ)

---

Q: What is the active ingredient in Perinal?

According to the official product information, Perinal contains Flibanserin. This ingredient is classified as a centrally-acting serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist.

---

Q: What is Perinal typically prescribed for?

Regulatory documents state that Perinal is prescribed for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is described as a low sexual desire that causes marked distress or interpersonal difficulty. This use is generally indicated when the low desire is not attributable to a co-existing medical or mental condition, relationship issues, or the effects of another medication or substance.

---

Q: How long does it take for Perinal to start working?

Studies and official information indicate that the benefits of Perinal are not immediate. The initial assessment of treatment effectiveness is typically performed after approximately 4 weeks of use. Regulatory labeling indicates that if improvement is not experienced after 8 weeks, discontinuation of the medication should be considered.

---

Q: What happens if I miss a dose of Perinal?

The official product information states that if a scheduled bedtime dose of Perinal is missed, the dose should not be taken the following morning. The patient should wait and take the next dose at the usual time that evening. It is stated that a patient should not take two doses to compensate for a missed dose.

---

Q: Can I drink alcohol while taking Perinal?

The official product information contains a strong warning regarding alcohol use while taking Perinal. Alcohol consumption increases the risk of severe hypotension (low blood pressure) and syncope (fainting), which may lead to accidental injury. Due to this risk, regulatory documents indicate that alcohol consumption should be avoided completely during treatment.

---

Q: Does Perinal interact with grapefruit?

Regulatory documents indicate that grapefruit and grapefruit juice should be avoided while taking Perinal. Grapefruit can interfere with the way the body processes the medication, potentially increasing the drug concentration in the body. This elevated concentration can lead to an increased risk of side effects, such as low blood pressure and fainting.

---

Q: Is it safe to drive after taking Perinal?

According to the official product information, Perinal can cause sleepiness (somnolence) and sedation, especially shortly after the dose. For this reason, the medication is advised to be taken at bedtime. It is advised that activities requiring mental alertness, such as driving or operating heavy machinery, be avoided until a person is certain of how the medication affects them.

How to Store and Dispose of Perinal (Hydrocortisone and Lidocaine)

Official regulatory documentation specifies mandatory conditions to maintain the stability and quality of Perinal Suppositories.

---

Official Storage Conditions

Requirement	Specific Rule
Temperature Limit	Must not be stored above 25 C.
Protection	Must be stored in the original package to protect from light.
Container Rule	Must be kept in the original package.
Stability Period	Defined by the expiry date stated on the blister and outer package.

---

Disposal Instructions

The regulatory label explicitly states that there are no special requirements for the disposal of the used medicine or any waste materials derived from the product. This means the disposal of unused or expired product should follow general local pharmaceutical waste guidelines.